However, addition of the Notch 2/3 targeting antibody tarextumab and etoposide to carboplatin or cisplatin in patients with SCLC receiving these drugs as the first line treatment did not improve the frequency of OR compared to placebo (NCT01859741). The gene discussed is NOTCH2; the disease is small cell lung carcinoma.